Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Insight into how Th17 cell growth influences development of immune responses

Insight into how Th17 cell growth influences development of immune responses

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Researchers identify four new genetic regions associated with Behcet's disease

Researchers identify four new genetic regions associated with Behcet's disease

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott receives FDA approval for Humira to treat ulcerative colitis

Abbott receives FDA approval for Humira to treat ulcerative colitis

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Questcor second quarter net sales increase to $112.5 million

Questcor second quarter net sales increase to $112.5 million

Herpes zoster vaccine recommendations questioned in patients on biologics

Herpes zoster vaccine recommendations questioned in patients on biologics

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Biomarkers predict progressive spinal damage in ankylosing spondylitis

Biomarkers predict progressive spinal damage in ankylosing spondylitis

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

Study identifies 5 biomarkers that may predict progression of spinal damage in AS patients

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

MD Bioproducts launches new subtype specific antibody as marker for AS

MD Bioproducts launches new subtype specific antibody as marker for AS

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Cervical spine CT exams unnecessary for simple assault and ground-level fall victims

Cervical spine CT exams unnecessary for simple assault and ground-level fall victims

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Questcor fourth quarter net sales increase to $75.5 million

Questcor fourth quarter net sales increase to $75.5 million